Actively Recruiting
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
Led by AbbVie · Updated on 2025-07-20
96
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.
CONDITIONS
Official Title
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Laboratory values meet the criteria specified in the protocol.
- General good health based on medical history, physical exam, vital signs, lab tests, and ECG.
- For Part 2 only: Healthy Han Chinese or Japanese individuals aged 18 to 65 years.
- Han Chinese participants must be first- or second-generation of full Chinese parentage, living outside China, maintaining a typical Chinese lifestyle and diet.
- Japanese participants must be first- or second-generation of full Japanese parentage, living outside Japan, maintaining a typical Japanese lifestyle and diet.
You will not qualify if you...
- History of any clinically significant illness, infection, major fever, hospitalization, or surgery within 30 days before first dose.
- Consumption of alcohol, grapefruit products, Seville oranges, starfruit products, or quinine/tonic water within 72 hours before study drug.
- Use of tobacco or nicotine products within 180 days before first dose.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Acpru /Id# 270279
Grayslake, Illinois, United States, 60030
Actively Recruiting
Research Team
A
ABBVIE CALL CENTER
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
12
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here